This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arora, P. D. Articles by McCulloch, C. A. G. Search for Related Content PubMed PubMed Citation Articles by Arora, P. D. Articles by McCulloch, C. A. G.

(American Journal of Pathology. 1999;155:2087-2099.)
© 1999 American Society for Investigative Pathology

Regular Articles

The Deletion of Transforming Growth Factor-ß-Induced Myofibroblasts Depends on Growth Conditions and Actin Organization

From the MRC Group In Periodontal Physiology, Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada

Myofibroblasts are important but transient mediators of normal wound contraction and are characterized phenotypically by their high levels of -smooth-muscle actin (SMA). During wound maturation, these cells disappear. We have examined the mechanisms that lead to myofibroblast deletion in a fibroblast culture model. Transforming growth factor-ß (TGF-ß) was used to increase SMA content in gingival fibroblasts (three- to sixfold). After replating TGF-ß-induced cells at low density with serum, there was a fivefold decrease in SMA protein content, SMA protein synthesis, and SMA mRNA as cells proliferated. These reductions were due to reduced SMA mRNA stability. For TGF-ß-induced cells plated at high density without serum (ie, quiescent conditions), protein content was reduced by only 20% over 12 days. TGF-ß protected SMA-positive cells against apoptosis in serum-free cultures. Those cells that were protected against apoptosis exhibited well-developed stress fibers enriched in SMA. We conclude that, in quiescent myofibroblasts, SMA protein turnover is slow, and cells are long-lived. In proliferative conditions SMA protein and mRNA turn over quickly, and the myofibroblast phenotype dissipates. The reduced apoptosis of myofibroblasts in quiescent conditions is due in part to the organization of SMA into stress fibers.

This article has been cited by other articles:

				Y. Lenga, A. Koh, A. S. Perera, C. A. McCulloch, J. Sodek, and R. Zohar Osteopontin Expression Is Required for Myofibroblast Differentiation Circ. Res., February 15, 2008; 102(3): 319 - 327. [Abstract] [Full Text] [PDF]

				T. Meyer-ter-Vehn, S. Sieprath, B. Katzenberger, S. Gebhardt, F. Grehn, and G. Schlunck Contractility as a Prerequisite for TGF-{beta}-Induced Myofibroblast Transdifferentiation in Human Tenon Fibroblasts Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 4895 - 4904. [Abstract] [Full Text] [PDF]

				P. Laplante, M.-A. Raymond, A. Labelle, J.-I. Abe, R. V. Iozzo, and M.-J. Hebert Perlecan Proteolysis Induces an {alpha}2beta1 Integrin- and Src Family Kinase-dependent Anti-apoptotic Pathway in Fibroblasts in the Absence of Focal Adhesion Kinase Activation J. Biol. Chem., October 13, 2006; 281(41): 30383 - 30392. [Abstract] [Full Text] [PDF]

				H.E. van Beurden, J.W. Von den Hoff, R. Torensma, J.C. Maltha, and A.M. Kuijpers-Jagtman Myofibroblasts in Palatal Wound Healing: Prospects for the Reduction of Wound Contraction after Cleft Palate Repair J. Dent. Res., October 1, 2005; 84(10): 871 - 880. [Abstract] [Full Text] [PDF]

				J. D. Lovelock, A. H. Baker, F. Gao, J.-F. Dong, A. L. Bergeron, W. McPheat, N. Sivasubramanian, and D. L. Mann Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H461 - H468. [Abstract] [Full Text] [PDF]

				R. Vittal, J. C. Horowitz, B. B. Moore, H. Zhang, F. J. Martinez, G. B. Toews, T. J. Standiford, and V. J. Thannickal Modulation of Prosurvival Signaling in Fibroblasts by a Protein Kinase Inhibitor Protects against Fibrotic Tissue Injury Am. J. Pathol., February 1, 2005; 166(2): 367 - 375. [Abstract] [Full Text] [PDF]

				G. A. Walker, K. S. Masters, D. N. Shah, K. S. Anseth, and L. A. Leinwand Valvular Myofibroblast Activation by Transforming Growth Factor-{beta}: Implications for Pathological Extracellular Matrix Remodeling in Heart Valve Disease Circ. Res., August 6, 2004; 95(3): 253 - 260. [Abstract] [Full Text] [PDF]

				N. A. Rice and L. A. Leinwand Skeletal myosin heavy chain function in cultured lung myofibroblasts J. Cell Biol., October 13, 2003; 163(1): 119 - 129. [Abstract] [Full Text] [PDF]

				J. Wang, M. Su, J. Fan, A. Seth, and C. A. McCulloch Transcriptional Regulation of a Contractile Gene by Mechanical Forces Applied through Integrins in Osteoblasts J. Biol. Chem., June 14, 2002; 277(25): 22889 - 22895. [Abstract] [Full Text] [PDF]

				J. Yamate, K. Sato, M. Ide, M. Nakanishi, M. Kuwamura, S. Sakuma, and S. Nakatsuji Participation of Different Macrophage Populations and Myofibroblastic Cells in Chronically Developed Renal Interstitial Fibrosis after Cisplatin-induced Renal Injury in Rats Vet. Pathol., May 1, 2002; 39(3): 322 - 333. [Abstract] [Full Text] [PDF]

				R. Abe, S. C. Donnelly, T. Peng, R. Bucala, and C. N. Metz Peripheral Blood Fibrocytes: Differentiation Pathway and Migration to Wound Sites J. Immunol., June 15, 2001; 166(12): 7556 - 7562. [Abstract] [Full Text] [PDF]

				J. Yamate, M. Maeda, S. J. Benn, J. E. Laithwaite, A. Allan, M. Ide, M. Kuwamura, T. Kotani, S. Sakuma, and J. Lamarre Differential Effects of Transforming Growth Factor-{beta}1, a Fibrogenic Factor, on Macrophage-Like Cells (HS-P) and Myofibroblastic Cells (MT-9) In Vitro Toxicol Pathol, June 1, 2001; 29(4): 483 - 491. [Abstract] [PDF]